17 compounds · from $62.99
Regulomaxxing — 17 Khavinson Organ-Targeted Short Peptides
Regulomaxxing is the Khavinson bioregulator series in full, seventeen vials of it. The premise is narrow and consistent: each peptide is two to four amino acids, modelled on the regulatory peptide pool of one specific organ, and theorised to restore that organ's protein-synthesis programme through direct interaction with tissue-specific gene promoters. Pinealon and Cortagen map to brain tissue, Cardiogen to heart, Livagen to liver, Prostamax to prostate, Thymogen to thymus, and so on across the lineup. The supporting work spans five decades out of the Saint Petersburg Institute of Bioregulation and Gerontology, but it is heavily concentrated in Russian-language publication and the English-language reviews Khavinson has authored are the practical entry point. Treat this shelf as research material and read the primary sources before drawing conclusions.
Pinealon 20mg
Cortagen 20mg
Cardiogen 20mg
Thymogen 20mg
Pinealon 10mg
Adamax 10mg
Vesugen 20mg
Livagen 20mg
Ovagen 20mg
Pancragen 20mg
Bronchogen 20mg
Chonluten 20mg
Vilon 20mg
Crystagen 20mg
Testagen 20mg
Prostamax 20mg
Vesilute 20mg
What the Khavinson Series Claims
The premise behind the bioregulators is narrow and consistent: each peptide is two to four amino acids, drawn from or modelled on the regulatory peptide pool of one specific organ, and theorised to restore that organ's protein-synthesis programme. Pinealon and Cortagen map to brain tissue, Cardiogen to heart, Livagen to liver, Prostamax to prostate, Thymogen to thymus, and so on across seventeen vials. The mechanism proposed is direct interaction with promoter regions of tissue-specific genes — short enough to enter the nucleus, specific enough to bind particular sequences.
Where the Evidence Actually Sits
The supporting work spans five decades out of the Saint Petersburg Institute of Bioregulation and Gerontology, and the volume is genuinely large. The problem for anyone evaluating it from outside is that it is heavily concentrated in Russian-language journals, much of it from a period and a publishing culture with different methodological expectations than a modern registered trial. Khavinson has authored English-language reviews that summarise the programme, and those are the practical entry point. Independent Western replication is sparse, which is the honest state of it.
Peptide Bioregulators vs Peptide Therapeutics
These compounds are not doing what BPC-157 or a GLP-1 agonist does. There is no receptor agonism in the conventional pharmacological sense and no dose-response curve of the kind the incretins produce. The proposed mechanism is regulatory rather than signalling — nudging transcription in a tissue rather than activating a receptor on it. That difference matters when reading protocols: bioregulator courses are typically short, cyclical, and low-dose, and stacking logic from the rest of the catalogue does not transfer cleanly.
The Seventeen-Vial Lineup
The full series stocked here covers pineal (Pinealon), cerebral cortex (Cortagen, Adamax), cardiovascular (Cardiogen, Vesugen), hepatic (Livagen), ovarian (Ovagen), pancreatic (Pancragen), bronchial (Bronchogen, Chonluten), thymic (Thymogen, Vilon, Crystagen), testicular (Testagen), prostatic (Prostamax) and urinary (Vesilute) targets. Pinealon and Cortagen are the two most frequently ordered, largely because the brain-tissue claims are the ones with the most accessible English-language write-ups behind them.
Regulomaxxing — Common Questions
What are Khavinson bioregulators?
They are very short peptides, two to four amino acids each, developed at the Saint Petersburg Institute of Bioregulation and Gerontology from the 1970s onward. Each one is modelled on the regulatory peptide pool of a specific organ and is theorised to restore that organ's protein-synthesis programme by interacting directly with tissue-specific gene promoters.
How is Regulomaxxing different from the other shelves here?
Every other shelf works through receptor agonism or a defined biochemical mechanism with a dose-response curve. The bioregulators propose a regulatory effect on transcription instead, which is why their protocols look different — short cyclical courses at low doses rather than sustained administration, and stacking logic from the rest of the catalogue does not carry over.
How strong is the evidence for these peptides?
The volume of published work is large and spans five decades, but it is concentrated almost entirely in Russian-language journals from a research tradition with different methodological conventions than a modern registered trial. Independent Western replication is sparse. Khavinson's own English-language reviews are the best entry point for evaluating it, and this shelf should be treated as research material.
Which bioregulator should be looked at first?
Pinealon and Cortagen are the two most frequently ordered from the series, mainly because the brain-tissue claims have the most accessible English-language literature behind them. Beyond that, the series is organ-targeted by design, so selection follows whichever tissue the research question concerns rather than any general-purpose ranking.